A banalização da razão, a falsa autonomia e o colapso da dúvida na era da inteligência artificial e do neoliberalismo ...

Que o sobrenome Bolsonaro volte ao pleito – ainda que por intermédio de Flávio Bolsonaro – é o mínimo que uma oposição ao ...

O escritor e ensaísta Luiz Felipe Pondé estreia nesta quinta-feira (11) na CasaFolha, a plataforma de streaming lançada pela ...

João Ribeiro de Almeida Borba é professor, Doutor em Filosofia pela PUC de São Paulo (2008) e Mestre em Filosofia também pela PUC de São Paulo (2000), Graduado em Filosofia pela USP (1996). Tem ...

Moderna Inc. fell Monday after the Food and Drug Administration said in a memo late last week it would place new restrictions on which vaccines hit the market. Vinay Prasad, a top FDA official, blamed ...

President Trump is reportedly planning to unveil a new proposal for addressing healthcare costs as soon as today. This as his administration tries to avert a spike in premiums driven by the expiration ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Vaccine-maker Moderna has become the most shorted company in the S&P 500, with its share price slumping to its ...

Targets readouts from nine ongoing Phase 2 and Phase 3 clinical studies in its oncology pipeline, including three Phase 3 programs for intismeran autogene Further improves 2026 and 2027 expected GAAP ...

Moderna is pruning three investigational vaccines from its pipeline, while also securing additional funding, giving the company more financial flexibility as it strives to hit 10% revenue growth in ...

Moderna, an mRNA specialist known for its COVID-19 vaccine Spikevax, is winding down development of three clinical mRNA programs, including two investigational vaccines for infectious diseases. The ...

With much of Moderna’s rise in this decade tied to its COVID-19 vaccine, the company has struggled in recent years to match the sales highs it experienced during the pandemic. Now, in an effort to ...

Shares of Moderna, Inc. (NASDAQ: MRNA) are falling Thursday. The Massachusetts-based biotech company made two significant announcements regarding its finances and business strategy. What To Know: ...